Capsules ready for Phase IIa study
PharmNovo is pleased to announce that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
The Phase IIa study will investigate the safety and efficacy of PN6047 in patients with neuropathic pain. The clinical trial application (CTA) has previously been submitted in Spain and submissions in Poland and the Czech Republic will follow shortly.
Although the study will be conducted in the EU, it is aligned with FDA requirements following a pre-IND (Investigational New Drug) meeting with the FDA, and an IND is currently being compiled.
This achievement represents a key step in advancing PN6047 into the next stage of clinical development. PharmNovo is now focused on progressing its clinical programme and generating data to support continued development and future partnering opportunities.
Read the full press release here:
Follow us: